close

Agreements

Date: 2011-06-07

Type of information: Commercialisation agreement

Compound: Ruconest® (Rhucin® in non-European territories - conestat alfa)

Company: Pharming Group (Netherlands) MegaPharm (Israel)

Therapeutic area: Rare diseases

Type agreement:

commercialisation

Action mechanism:

Ruconest® is a human protein (plasma protein C1-inhibitor ) developed through Pharming’s proprietary technology where the human protein is expressed in milk of transgenic rabbits.

Disease: acute angioedema attacks in patients with Hereditary Angioedema (HAE)

Details:

Pharming Group has entered into an agreement with MegaPharm Ltd, a privately owned Israeli pharmaceutical company, for the commercialization of Ruconest® (recombinant human C1 inhibitor) in Israel for the treatment of acute angioedema attacks in patients with Hereditary Angioedema (HAE). Under the agreement, MegaPharm will pay Pharming for completion of certain commercial, regulatory and clinical milestones. MegaPharm will purchase its commercial supply of Ruconest from Pharming at a supply price, based on a percentage of net sales of Ruconest®. The number of HAE patients in Israel is estimated at approximately 250. MegaPharm anticipate to launch Ruconest® in 2012.


Financial terms:

Financial details were not disclosed.

Latest news:

Is general: Yes